Skip to main content
SpringerLink
Log in

Homocysteine and blood pressure

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Several studies, some population-based, have linked plasma homocysteine levels to blood pressure, especially systolic pressure. The strength of this association is weak, but may be underestimated due to inaccurate blood pressure measurements. In addition, the association may be confounded by renal function. Observations that homocysteine-lowering therapies with folic acid-based treatments have been followed by decreases in blood pressure, however, raise the possibility that the link between homocysteine and blood pressure is real, which is important as homocysteine levels can easily be lowered by folic acid-based regimens. Mechanisms that could explain the relationship between homocysteine and blood pressure include increased arterial stiffness, endothelial dysfunction with decreased availability of nitric oxide, low folate status, and insulin resistance. So far, however, no evidence has been provided that these mechanisms are operative in humans. Ongoing large intervention studies with homocysteine-lowering vitamins may indicate whether blood pressure is indeed lowered by these vitamins, whether the blood pressure decrease, if any, is explained by the decrease in homocysteine levels, and whether a vitamin treatment-associated decrease in cardiovascular morbidity (if any) is explained by the decrease in blood pressure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305–1315.

    Article  PubMed  CAS  Google Scholar 

  2. Eikelboom JW, Lonn E, Genest J Jr, et al.: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999, 131:363–375.

    PubMed  CAS  Google Scholar 

  3. Vermeulen EG, Stehouwer CD, Twisk JW, et al.: Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000, 355:517–522.

    Article  PubMed  CAS  Google Scholar 

  4. Schnyder G, Roffi M, Pin R, et al.: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001, 345:1593–1600.

    Article  PubMed  CAS  Google Scholar 

  5. van Dijk RA, Rauwerda JA, Steyn M, et al.: Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001, 21:2072–2079. This prospective study draws attention to the potential blood pressure-lowering effect of homocysteine-lowering vitamins and investigates possible underlying mechanisms.

    PubMed  Google Scholar 

  6. van Guldener C, Stehouwer CD: Homocysteine-lowering treatment: an overview. Expert Opin Pharmacother 2001, 2:1449–1460.

    Article  PubMed  Google Scholar 

  7. Bots ML, Launer LJ, Lindemans J, et al.: Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J Intern Med 1997, 242:339–347.

    Article  PubMed  CAS  Google Scholar 

  8. Jacques PF, Bostom AG, Wilson PW, et al.: Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001, 73:613–621.

    PubMed  CAS  Google Scholar 

  9. Nygard O, Vollset SE, Refsum H, et al.: Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995, 274:1526–1533.

    Article  PubMed  CAS  Google Scholar 

  10. Hoogeveen EK, Kostense PJ, Beks PJ, et al.: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998, 18:133–138.

    PubMed  CAS  Google Scholar 

  11. Osganian SK, Stampfer MJ, Spiegelman D, et al.: Distribution of and factors associated with serum homocysteine levels in children: Child and Adolescent Trial for Cardiovascular Health. JAMA 1999, 281:1189–1196. This large cross-sectional study shows that homocysteine is independently associated with systolic blood pressure in schoolchildren aged 13 to 14 years, suggesting a true relationship.

    Article  PubMed  CAS  Google Scholar 

  12. Malinow MR, Levenson J, Giral P, et al.: Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995, 114:175–183.

    Article  PubMed  CAS  Google Scholar 

  13. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C: High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997, 96:1745–1749.

    PubMed  CAS  Google Scholar 

  14. Fiorina P, Lanfredini M, Montanari A, et al.: Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. Am J Hypertens 1998, 11:1100–1107.

    Article  PubMed  CAS  Google Scholar 

  15. Sheu WH, Lee WJ, Chen YT: Plasma homocysteine concentrations and insulin sensitivity in hypertensive subjects. Am J Hypertens 2000, 13:14–20.

    Article  PubMed  CAS  Google Scholar 

  16. Lip GY, Edmunds E, Martin SC, et al.: A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage. Am J Hypertens 2001, 14:627–631.

    Article  PubMed  CAS  Google Scholar 

  17. Davis KR, Pearson H, Moat S, et al.: Acute hyperhomocysteinaemia affects pulse pressure but not microvascular vasodilator function. Br J Clin Pharmacol 2001, 52:327–332.

    Article  PubMed  CAS  Google Scholar 

  18. Nappo F, De Rosa N, Marfella R, et al.: Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999, 281:2113–2118.

    Article  PubMed  CAS  Google Scholar 

  19. Wilkinson IB, Megson IL, MacCallum T, et al.: Acute methionine loading does not alter arterial stiffness in humans. J Cardiovasc Pharmacol 2001, 37:1–5.

    Article  PubMed  CAS  Google Scholar 

  20. Graham IM, Daly LE, Refsum HM, et al.: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997, 277:1775–1781.

    Article  PubMed  CAS  Google Scholar 

  21. Stehouwer CD, Weijenberg MP, van den Berg M, et al.: Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998, 18:1895–1901.

    PubMed  CAS  Google Scholar 

  22. Verhoef P, Hennekens CH, Malinow MR, et al.: A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994, 25:1924–1930.

    PubMed  CAS  Google Scholar 

  23. van Guldener C, Stehouwer CD: Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost 2000, 26:281–289. A concise review on the vascular effects of homocysteine.

    Article  PubMed  Google Scholar 

  24. Symons JD, Mullick AE, Ensunsa JL, et al.: Hyperhomocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol 2002, 22:772–780.

    Article  PubMed  CAS  Google Scholar 

  25. Rolland PH, Friggi A, Barlatier A, et al.: Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995, 91:1161–1174.

    PubMed  CAS  Google Scholar 

  26. Lambert J, van den Berg M, Steyn M, et al.: Familial hyperhomocysteinaemia and endothelium-dependent vasodilatation and arterial distensibility of large arteries. Cardiovasc Res 1999, 42:743–751.

    Article  PubMed  CAS  Google Scholar 

  27. Smilde TJ, van den Berkmortel FW, Boers GH, et al.: Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 1998, 18:1958–1963.

    PubMed  CAS  Google Scholar 

  28. Bortolotto LA, Safar ME, Billaud E, et al.: Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension 1999, 34:837–842. This study shows that homocysteine is associated with aortic stiffness in hypertensive individuals, independent of age, blood pressure, and renal function.

    PubMed  CAS  Google Scholar 

  29. van Guldener C, Lambert J, Janssen MJ, et al.: Endotheliumdependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 1997, 12(Suppl 2):14–18.

    PubMed  Google Scholar 

  30. Blacher J, Demuth K, Guerin AP, et al.: Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 1998, 18:535–541.

    PubMed  CAS  Google Scholar 

  31. Arcaro G, Fava C, Dagradi R: Acute hyperhomocysteinemia induces a reduction in arterial distensibility and compliance. J Hypertens 2000, 18(Suppl 2):S198.

    Google Scholar 

  32. van Guldener C, Lambert J, ter Wee PM, et al.: Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy. Clin Nephrol 2000, 53:33–41.

    PubMed  Google Scholar 

  33. Mangoni AA, Ouldred E, Swif CG, et al.: Vascular and blood pressure effects of folic acid in older patients with cardiovascular disease. J Am Geriatr Soc 2001, 49:1003–1004.

    Article  PubMed  CAS  Google Scholar 

  34. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998, 338:1042–1050.

    Article  PubMed  CAS  Google Scholar 

  35. Schiffrin EL: A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol 2001, 38(Suppl 2):S3-S6.

    PubMed  CAS  Google Scholar 

  36. Forte P, Copland M, Smith LM, et al.: Basal nitric oxide synthesis in essential hypertension. Lancet 1997, 349:837–842.

    Article  PubMed  CAS  Google Scholar 

  37. Chao CL, Kuo TL, Lee YT: Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation 2000, 101:485–490.

    PubMed  CAS  Google Scholar 

  38. Usui M, Matsuoka H, Miyazaki H, et al.: Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci (Colch) 1999, 96:235–239.

    Article  CAS  Google Scholar 

  39. Chambers JC, McGregor A, Jean-Marie J, et al.: Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999, 99:1156–1160.

    PubMed  CAS  Google Scholar 

  40. Tawakol A, Omland T, Gerhard M, et al.: Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997, 95:1119–1121.

    PubMed  CAS  Google Scholar 

  41. Woo KS, Chook P, Lolin YI, et al.: Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997, 96:2542–2544.

    PubMed  CAS  Google Scholar 

  42. Valk-de Roo GW, Stehouwer CD, Lambert J, et al.: Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal women. Clin Chem 1999, 45:1200–1205.

    Google Scholar 

  43. Hanratty CG, McAuley DF, McGrath LT, et al.: Hyperhomocysteinaemia in young adults is not associated with impaired endothelial function. Clin Sci (Lond) 2001, 100:67–72.

    Article  CAS  Google Scholar 

  44. van Guldener C, Janssen MJ, Lambert J, et al.: Endotheliumdependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 1998, 13:1782–1786.

    Article  PubMed  Google Scholar 

  45. Bellamy MF, McDowell IF, Ramsey MW, et al.: Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest 1999, 29:659–662.

    Article  PubMed  CAS  Google Scholar 

  46. Title LM, Cummings PM, Giddens K, et al.: Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000, 36:758–765.

    Article  PubMed  CAS  Google Scholar 

  47. Verhaar MC, Wever RM, Kastelein JJ, et al.: 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998, 97:237–241.

    PubMed  CAS  Google Scholar 

  48. van Guldener C, Janssen MJ, Lambert J, et al.: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998, 13:106–112.

    Article  PubMed  Google Scholar 

  49. van Guldener C, Janssen MJ, Lambert J, et al.: Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Periton Dial Int 1998, 18:282–289.

    Google Scholar 

  50. van Guldener C, Stehouwer CD: Diabetes mellitus and hyperhomocysteinemia. SeminVasc Med 2002, 2:87–95.

    Google Scholar 

  51. Hoogeveen EK, Kostense PJ, Jakobs C, et al.: Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000, 101:1506–1511.

    PubMed  CAS  Google Scholar 

  52. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H: The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996, 56:41–46.

    PubMed  CAS  Google Scholar 

  53. van Guldener C, Stam F, Stehouwer CD: Homocysteine metabolism in renal failure. Kidney Int 2001, 59(Suppl 78): S234-S237.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Vrije Universiteit Medical Centre, PO Box 7057, 1007, MB, Amsterdam, The Netherlands

    Coen van Guldener MD, PhD

Authors
  1. Coen van Guldener MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prabath W. B. Nanayakkara MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Coen D. A. Stehouwer MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Guldener, C., Nanayakkara, P.W.B. & Stehouwer, C.D.A. Homocysteine and blood pressure. Current Science Inc 5, 26–31 (2003). https://doi.org/10.1007/s11906-003-0007-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0007-z

Keywords

Search

Navigation